AR-13324 Phase 2 study

A prospective, double-masked, randomized, multicenter, parallel-group study for subjects with open angle glaucoma or ocular hypertension

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2080224561

Enrollment

208

Registered

2019-02-13

Start date

2019-03-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

open angle glaucoma or ocular hypertension

Interventions

investigational material(s) Generic name etc : AR-13324 INN of investigational material : netarsudil Therapeutic category code : 131 Agents for ophthalmic use Dosage and Administration for Investigati

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: - Diagnosis of open-angle glaucoma (OAG) or ocular hypertension (OHT) in both eyes - Medicated intraocular pressure (IOP) greater than or equal to 14 mmHg in at least one eye and less than 30 mmHg in both eyes Etc.

Exclusion criteria

Exclusion criteria: - Clinically significant ocular disease which might interfere with interpretation of the study efficacy endpoints or with safety assessments - Pseudoexfoliation or pigment dispersion component glaucoma, history of angle closure glaucoma, or narrow angles - Women of childbearing potential who are pregnant, nursing, or planning a pregnancy Etc.

Design outcomes

Primary

Measure	Time frame
safety efficacy Ocular symptoms/adverse events	—

Secondary

Measure	Time frame
efficacy IOP	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026